Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. (XERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh991q22026earningsrelease.htm EX-99.1 Document Exhibit 99.1 XERIS BIOPHARMA REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Total revenue increased to over $92 million Net product revenue increased 34% year-over-year to over $91 million Recorlev net revenue increased 81
Xeris Biopharma Holdings, Inc. (XERS) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. xers-20260715 ☐ 0001867096 0001867096 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Jul
McCulloch Kevin (See Remarks) sold 90,000 shares of Xeris Biopharma Holdings, Inc. (XERS) at $8.03 ($0.72M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 1 news story mentioning XERS (Xeris Biopharma Holdings, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent XERS coverage spans insider activity, corporate actions and earnings.
In the last 30 days, XERS insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($254K). The most active reporter was McCulloch Kevin, See Remarks, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Guidance tightening plus strong Recorlev demand and gross margin improvement are likely to support near-term sentiment, while the one-time convertible-note fair value charge distorts GAAP loss.
The filing discloses dilution from note-to-equity conversion/exchange and confirms the company has no 2028 notes outstanding after July 15, 2026.
The filing is a routine insider sale under a pre-arranged 10b5-1 plan, with limited direct signal for near-term fundamentals.
Board expansion and leadership restructuring are incremental governance updates; they may slightly affect sentiment but do not change near-term fundamentals in the filing.
The filing signals a balance-sheet/financing action that can dilute shareholders (stock component) while reducing near-term debt burden.
alphai scores every news story that mentions XERS with an AI model for sentiment and relevance, and aggregates insider trades from Xeris Biopharma Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Xeris Biopharma Holdings, Inc. (XERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh991q22026earningsrelease.htm EX-99.1 Document Exhibit 99.1 XERIS BIOPHARMA REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Total revenue increased to over $92 million Net product revenue increased 34% year-over-year to over $91 million Recorlev net revenue increased 81
6 min readXeris Biopharma Holdings, Inc. (XERS) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. xers-20260715 ☐ 0001867096 0001867096 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Jul
3 min readMcCulloch Kevin (See Remarks) sold 90,000 shares of Xeris Biopharma Holdings, Inc. (XERS) at $8.03 ($0.72M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
1 min readXeris Biopharma Holdings, Inc. (XERS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. xers-20260629 ☐ 0001867096 0001867096 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Jun
2 min readXeris Biopharma Holdings, Inc. (XERS) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. xers-20260610 ☐ 0001867096 0001867096 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Jun
3 min readPERSKY MARLA sold 15,500 shares of Xeris Biopharma Holdings, Inc. (XERS) at $5.90 on 2026-06-03 under a Rule 10b5-1 trading plan.
2 min readHALKUFF DAWN sold 20,000 shares of Xeris Biopharma Holdings, Inc. (XERS) at $6.09 ($0.12M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
2 min readBORMANN-KENNEDY BARBARA-JEAN ANNE sold 16,000 shares of Xeris Biopharma Holdings, Inc. (XERS) at $6.09 on 2026-06-04 under a Rule 10b5-1 trading plan.
2 min readJOHNSON JOHN sold 15,000 shares of Xeris Biopharma Holdings, Inc. (XERS) at $6.09 on 2026-06-04 under a Rule 10b5-1 trading plan.
2 min readXeris Biopharma Holdings, Inc. (XERS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. xers-20260604 ☐ 0001867096 0001867096 2026-06-04 2026-06-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Jun
2 min read